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Medicine, University of Edinburgh, Edinburgh, United Kingdom
Despite extensive research over many decades, human breast cancer remains a
major worldwide health concern. Advances in pre-clinical and clinical research has
led to significant improvements in recent years in how we manage breast cancer
patients. Although survival rates of patients suffering from localized disease has improved
significantly, the prognosis for patients diagnosed with metastatic disease remains poor
with 5-year survival rates at only 25%. In vitro studies using immortalized cell lines and in
vivo mouse models, typically using xenografted cell lines or patient derived material, are
commonly used to study breast cancer. Although these techniques have undoubtedly
increased our molecular understanding of breast cancer, these research models have
significant limitations and have contributed to the high attrition rates seen in cancer
drug discovery. It is estimated that only 3–6% of drugs that show promise in these
pre-clinical models will reach clinical use. Models that can reproduce human breast
cancermore accurately are needed if significant advances are to be achieved in improving
cancer drug research, treatment outcomes, and prognosis. Canine mammary tumors
are a naturally-occurring heterogenous group of cancers that have several features in
common with human breast cancer. These similarities include etiology, signaling pathway
activation and histological classification. In this review article we discuss the use of
naturally-occurring canine mammary tumors as a translational animal model for human
breast cancer research.
Keywords: canine mammary cancer, comparative oncology, human breast cancer, in vivo models, translational
models
INTRODUCTION
Cancer is a disease that occurs throughout the world, creating widespread social and economic
burdens. Although advances in pre-clinical and clinical research are improving cancer diagnosis
and treatment, the disease remains a significant cause of death throughout the world. In 2018
it was estimated that ∼18 million new cancer cases were diagnosed and nearly 10 million
cancer-related deaths occurred (1). Diagnostic and treatment approaches for cancer patients are
constantly evolving, particularly in recent years due to increased interest in precision medicine
(2). This concept uses disease biomarkers, phenotypes, molecular signatures, lifestyle and the
environment to classify individual patients according to their differences in disease susceptibility,
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treatment responses and prognosis, ultimately allowing us to
identify cohorts of patients that are more likely to respond to
specific treatments and improve clinical outcomes (3). In order
to achieve the goals of precision medicine and enable a move
away from the traditional one-size-fits-all approach to cancer
management we need to continually improve our understanding
of cancer biology during its development and progression.
This review will discuss the advantages of employing naturally-
occurring canine mammary tumors as a translational animal
model for human breast cancer and how their use can improve
breast cancer research.
Human Breast Cancer Subtypes
Human breast cancer (HBC) is a genetically and clinically
heterogeneous disease (4). Breast cancer is the most commonly
diagnosed cancer in women, with ∼2 million new cases and
600,000 deaths occurring worldwide in 2018 (1). Survival rates
continue to improve due to early diagnosis, advancements in
surgical techniques and through the use of targeted therapies.
Estimates of 5-year survival rates are ∼97% for stage I, 88% for
stage II and 70% for stage III (disease confined to local breast
tissue or regional lymph nodes) (5). Despite advances in HBC
management, the survival for metastatic stage IV disease (disease
identified within distant organs or lymph nodes) remains poor at
∼25% (5). Following a diagnosis of breast cancer, classification
systems based on histological grading or molecular subtyping are
commonly used to account for tumor heterogeneity, providing
predictive and prognostic information which can influence a
patient’s treatment plan (6).
Histological classification systems categorize HBC into
invasive and in situ carcinomas. Carcinomas in situ (CIS) are
breast cancers in which malignant cells proliferate but remain
confined within the basal membrane of the breast’s terminal
duct lobular units. These cancers can be sub-classified as either
lobular or ductal (LCIS or DCIS). DCIS is the most common
presentation and is typically characterized by the expression of
E-cadherin. DCIS can be classified into 5 specific architectural
subtypes (comedo, cribiform, micropapillary, papillary and
solid) (7). Histological classification of DCIS and LCIS can
be further evaluated by grading the expression levels of
progesterone receptor (PR), estrogen receptor (ER), epidermal
growth factor receptor 2 (ErbB2/HER2) (8), epidermal growth
factor receptor (EGFR) and p53 (9–11). Invasive carcinomas can
be histologically classified as invasive lobular, infiltrating ductal,
ductal/lobular, tubular, mucinous, papillary and medullary (6).
Infiltrating ductal carcinoma is the most common presentation
of these subtypes, accounting for 70–80% of all invasive lesions
(12). Assessment of ER, PR and HER2 expression, often referred
to as receptor status, in invasive carcinomas provides an insight
into the likely drivers of the disease and can determine the use
of targeted therapies for specific cohorts of patients (11, 13).
Examples of drug selection based on receptor status would
include the use trastuzumab for HER2+ patients and aromatase
inhibitors or tamoxifen for ER+/PR+ patients (6, 14–16).
Molecular classification systems aim to predict a tumors
response to specific therapies. Largely based on microarray-
based gene expression analysis, several intrinsic HBC molecular
subtypes have been identified which have been shown to differ
in treatment responses and predict overall survival (OS) and
disease-free survival (DFS) (17–20). These subtypes include
normal breast-like, HER2+, luminal A, luminal B, “claudin-
low” and basal (17–19, 21). The ER+ subtypes (luminal A and
luminal B) differ in clinical outcomes and patient survival. This
molecular stratification is an important consideration, as clinical
assessment of infiltrating ductal carcinomas using ER, PR, and
HER2 receptor status cannot separate the two ER+ subtypes (6).
Despite the predictive abilities of this molecular classification, its
reliance on genome sequencing or microarray analysis means it
remains cost-prohibitive for use in clinical practice. To overcome
this obstacle, several studies have identified smaller gene sets
which can be used to classify HBC into subtypes and predict
prognosis or response to treatment. These clinically-available
tests include the OncotypeDX 21-gene recurrence score (22),
the BreastOncPx 14-gene distant metastasis signature (23) and
the MammaPrint 70-gene prognosis signature (24). A 50-gene
signature called PAM50 which has been shown to classify HBC
into subtypes has improved the ability to predict recurrence
of ER+/lymph node− patients compared to models using only
clinical variables (25, 26).
Human Breast Cancer Treatment
Treatment of HBC can be administered either locally or
systemically, depending largely on factors such as subtype and
stage of disease. Typically, early and locally-advanced HBC is
treated with surgery followed by adjuvant radiotherapy (RT),
chemotherapy and/or endocrine therapy. RT with curative intent
or as palliative treatment is estimated to benefit up to 83%
of patients (27). Studies have also shown that whole-breast
RT following breast-conserving surgery (BCS) provides local
control and survival rates equivalent to mastectomy (28–30),
with added advantages of improved cosmetic outcomes and
reduced side effects. RT treatment plans typically involve the
delivery of radiation to the tumor site in multiple fractions over
a period of several weeks; the standard adjuvant RT fractionation
regimen following BCS is 25 fractions of 2Gy over 5 weeks, or
hypofractionated regimens consisting of a total of 40Gy delivered
in 15 fractions over 3 weeks (31). Although overall 5-year survival
rates after RT are ∼80%, unfortunately around 30% of these
patients will develop metastatic disease or local recurrence. It is
these patients that have extremely poor 5 year survival rates (32).
Chemotherapy involves the administration of cytotoxic
drugs that damage cellular targets such as DNA and
tubulin in replicating cells. Many different chemotherapy
drugs are available for use in HBC which can be given
alone or in combination (cyclophosphamide, epirubicin, 5-
flurouracil, methotrexate, doxorubicin, docetaxel, gemcitabine).
Unfortunately, these drugs can cause significant side
effects such as vomiting, alopecia, weight loss, fatigue, and
immunosuppression (33). As a result of these wide-ranging side
effects, treatments are usually given in cycles over a period of
between 1–5 days, followed by a break of up to 4 weeks. Up to
8 treatment cycles may be given to breast cancer patients (34).
Chemotherapy can be given prior to surgery (neoadjuvantly) to
shrink the tumor before surgery (35) or after surgery (adjuvantly)
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in an attempt to prevent metastasis or recurrence. Adjuvant
chemotherapy has been shown to improve overall patient
survival by∼10% (36).
Various types of hormone treatments are available for ER+
breast cancers depending on whether the patient has gone
through menopause or not. These therapies aim to block
either the synthesis of the hormone estrogen or prevent its
binding to ER. Prior to the menopause estrogen is produced
primarily in the ovaries; this synthesis can be prevented
either surgically by removing the ovaries (oophorectomy) or
with endocrine therapies such as the gonadotropin-releasing
hormone agonist goserelin (ZoladexTM). However, the most
common therapeutic tools used in the pre-menopausal setting
are anti-oestrogens targeting the ER. Selective estrogen receptor
modulators (SERMs), such as tamoxifen, are commonly used
(37); they work by blocking the ER, thereby removing the
growth-promoting effects of estrogen on the tumor. Fulvestrant
(FaslodexTM) is an example of a selective estrogen receptor
down regulator (SERD) that both inhibits ER and accelerates
its degradation (38). In post-menopausal women estrogen is
synthesized from androgens in fat cells, through a reaction
catalyzed by the enzyme aromatase (39). Letrozole (FemaraTM),
anastrozole (ArimidexTM) and exemestane (AromasinTM) are
examples of aromatase inhibitors that work either by competing
with substrates binding to aromatase, or by mimicking the
substrates of aromatase and inactivating the enzyme. The overall
result is to reduce the amount of estrogen produced and thus
inhibit tumor growth (39). Post-menopausal women can also be
treated with SERMs or SERDs to block the effect of the ER in
cancer cells.
Targeted therapies have been developed to disrupt signaling
pathways that are over-expressed or dysregulated in certain
breast cancers (40). HER2 protein overexpression or gene
amplification occurs in up to 34% of invasive breast cancers
(41–43), leading to activation of numerous signaling pathways
that are associated with cell growth and proliferation (44).
Prognosis for patients presenting with HER2-overexpressing
breast tumors has improved significantly since the advent of
treatments targeting this receptor. Trastuzumab (HerceptinTM)
and Pertuzumab (PerjetaTM) are monoclonal antibodies that bind
to HER2 (45, 46) and block the cellular signaling pathways
initiated by the receptor, thereby inhibiting the growth and
survival of HER2-dependant tumors (47). Trastuzumab can be
given in neoadjuvant, adjuvant and metastatic settings, and can
improve OS of HER2-overexpressing breast cancer patients (48).
Lapatinib (TykerbTM), a dual tyrosine kinase inhibitor of HER2
and EGFR, is another example of targeted therapy in clinical
use (49). Both trastuzumab and lapatinib have been combined
either together (50, 51) or with chemotherapy (52, 53) or
hormone therapy (52, 54), leading to improved patient outcomes
compared to single agent treatment. Other forms of targeted
therapy involving trastuzumab include trastuzumab emtansine
(KadcylaTM), which consists of a monoclonal antibody combined
to a chemotherapeutic drug. With this treatment, trastuzumab
directs the conjugate to the HER2-overexpressing breast cancer
cells, inhibiting HER2 signaling, while the emtansine causes
cancer cell death through impeding microtubule assembly
(55). Another instance of a targeted therapy in clinical use
is everolimus (AfinitorTM); this drug inhibits the mammalian
target of rapamycin (mTOR) pathway, which is involved in
the regulation of the cell cycle, thereby inhibiting cancer cell
growth (56). Palbocicib (IbranceTM), Ribociclib (KisqaliTM), and
Abemaciclib (VerzeniosTM) are selective inhibitors of the cyclin-
dependent kinases CDK4 and CDK6 and are one of the newer
classes of drugs to gain clinical approval for use in HBC patients.
In post-menopausal women with ER+/HER2− advanced breast
cancer palbocicib can increase progression-free survival times
when given in combination with letrozole compared with using
letrozole alone (57).
Limitations in Current Pre-clinical Cancer
Research
In the United States of America it is currently estimated that drug
development from inception to regulatory approval requires∼13
years and between $1.8–2.6 billion (58); despite this enormous
investment, between 86–95% of drugs fail to show efficacy
or gain approval for use. The majority of agents fail during
clinical trials, after a considerable amount of time and money
has already been invested in drug development (58, 59). The
situation is even worse for the development of new cancer
drugs, where only 3–6% of drugs reach clinical use (59). There
are numerous limitations associated with traditional pre-clinical
studies which tend to focus on cancer cells grown in 2D or
3D cultures (60) or murine xenograft models (61, 62) to assess
the efficacy of cancer agents; these limitations have contributed
to these high drug attrition rates. One method by which
traditional drug development strategies could be improved is to
integrate translational pre-clinical animal models into the drug
development process at an early stage. These models provide
an opportunity to evaluate all aspects of drug development,
ranging from efficacy, pharmacokinetics/dynamics and toxicity
assessment, through to formulating dosing schedules. These
studies could be completed before drugs are taken into more
expensive and time-consuming human clinical studies. The early
discovery of drug failures would allow drug refinement prior to
human clinical studies and ultimately reduce the failure rates
observed in these trials (Figure 1).
Canine Comparative Oncology
Comparative oncology enables the investigation of human
cancers by using similar cancers that occur naturally in animals.
The dog is an excellent example of comparative oncology,
as the species develops numerous tumors that have similar
clinicopathological features or incidence rates to specific human
cancers (63–65). Risk factors involved in carcinogenesis are also
similar between the two species, including environmental toxins
(dogs and humans will be exposed to similar carcinogens as they
share a common living environment), obesity and advancing age
(66). The advantages of studying cancers in this species over
current pre-clinical models are substantial and are largely due to
the tumors developing naturally in the presence of a functioning
immune system (34).
The popularity of keeping dogs as pets has meant that
there are ∼12 million pet dogs in the UK (67); this large
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FIGURE 1 | Schematic diagram outlining the integration of human and canine research programmes to improve current drug development strategies. The typical
course of human drug research and development is very linear, progressing through in vitro target identification and validation right through to phase 0, I, II, III, and IV
clinical trials. Unfortunately, most drugs which show promise in pre-clinical studies subsequently fail to show efficacy in clinical trials. At this point a substantial amount
of time and money has been spent, which can ultimately deter drug companies from developing new therapeutics. The integration of translational canine studies into
human drug development programmes could help identify drug failures sooner or allow for drug refinement prior to human clinical studies. Shorter disease-free
progression times seen in dogs also allows for rapid conclusion of the clinical trials that can incorporate assessment of drug activity, toxicity, pharmacokinetics,
pharmacodynamics, dose regimens, combination therapies and histology.
population therefore provides a valuable resource opportunity.
The shorter lifespan of dogs compared to humans enables
researchers to study cancers that develop after a few years instead
of decades, a time course that is sufficient to allow comparison
of treatment responses while still being short enough to ensure
rapid conclusion of the clinical trials. Dogs are also more
comparable with humans than rodents in terms of size, anatomy,
physiology, metabolism, immunology and genetics. Sequencing
of the canine genome (99% complete, ∼2.5 billion base pairs)
(68) has shown that there are greater similarities between dog
and human gene sequences than compared with mice (69).
Procedures that are commonly used in human medicine such
as sample collection, surgery and imaging can be easily used in
dogs but are harder to apply to rodent models. For these reasons
dogs are increasingly being regarded as an excellent model for
use in translational cancer research and have been shown to
be a highly-predictive model for drug development in humans
(63, 65, 70).
Canine Mammary Cancer
Canine mammary tumors (CMT) are the most commonly
diagnosed cancer in female dogs; accounting for almost 50%
of all canine neoplasms (71). The incidence rate per year
is ∼198 cases in every 100,000 dogs (66); this rate is
higher than that seen in humans, where the annual incidence
of HBC is 85 cases per 100,000 women (1). Taking into
account the different lifespans of the two species, the highest
incidence of mammary tumor development is similar between
dogs (8–11 years) and humans (50–58 years); this rate has
been shown to increase with age, with the disease rarely
diagnosed before 5 and 25 years of age in dogs and humans,
respectively (72–76).
The hormonal etiology of CMT has been well-established
and has largely been based on an initial study looking at the
incidence of CMT in intact and spayed (ovariohysterectomised)
female dogs. This study found that CMT developed in ∼0.5%
of female dogs that were spayed before their first season, with
levels rising to 8 and 26% when dogs were spayed either after
their first or second season. Furthermore, spaying dogs following
their second season had no protective effect on the risk of
developing malignant mammary tumors (77). Diet and obesity
have also been shown to affect CMT incidence rates. One study
showed that if dogs were classified as thin at 9–12 months of
age, they had a significantly reduced risk for mammary tumor
development compared with control dogs (the risk was reduced
by 99 and 40% in spayed and intact dogs, respectively) (78).
A further study found that dogs given a diet high in red meat
and dogs that were obese at 1 year old were at an increased
risk of developing mammary dysplasia and tumors (79). In post-
menopausal women, obesity is suggested to be a risk factor for
breast cancer development through raising circulating estrogen
levels and increasing local estrogen production by aromatases
(80, 81). It is possible that obesity escalates the risk for mammary
tumors in dogs through similar mechanisms, especially as both
canine studies indicated that obesity has the greatest effect on
mammary tumor development if present early in a dog’s life. This
may be due to hormones having the most damaging effects on
developing mammary tissue at this stage in a dog’s life.
Histology of Canine Mammary Cancer
Histological diagnosis remains the most common method for
classifying CMT. Periodic reviews have led to modifications
of the original histological classification system first published
in 1974 (82). One such modification was the World Health
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TABLE 1 | The different types of malignant and benign canine mammary tumors based on the WHO classification system [adapted from Misdorp et al. (83)].
Histological classification Description
MALIGNANT MAMMARY TUMORS
Carcinomas
In situ carcinoma No invasion of the basement membrane
Complex carcinoma Presence of luminal epithelial and myoepithelial components
Simple carcinoma: Composed of one cell type, resembling either luminal epithelial, or myoepithelial cells. Often invasive with lymphatic and/or
haematogenous spread. Increasing malignancy from tubulopapillary to solid to anaplastic tumors
Tubulopapillary carcinoma Characterized by tubules and/or papillary projections
Solid carcinoma Characterized by the arrangement of tumor cells in solid sheets, cords or nests
Anaplastic carcinoma Characterized by highly infiltrative pleomorphic epithelial cells
Spindle cell carcinoma Spindle cells arranged in epithelial patterns
Squamous cell carcinoma Characterized by solid sheets and cords of cells with squamous differentiation
Mucinous carcinoma Characterized by mucin production
Lipid-rich carcinoma Characterized by cells with vacuolated cytoplasm containing large amounts of lipids
Sarcomas
Fibrosarcoma Fibroblasts with collagen production
Osteosarcoma Characterized by neoplastic cellular osteoid and/or bone formation
Chondrosarcoma Very rare
Liposarcoma Very rare
Mixed
Carcinosarcoma Carcinomatous and sarcomatous components
Carcinoma/sarcoma in benign
tumors
Foci of malignant cells within a complex adenoma or benign mixed tumor
BENIGN MAMMARY TUMORS
Adenomas
Simple Well differentiated luminal epithelial or myoepithelial cellular tumor
Complex Characterized by luminal epithelial and myoepithelial cells
Basaloid Uniform cords and clusters of basaloid epithelial cells
Fibroadenomas
Low/high cellularity Mixed luminal epithelial cells, stromal cells and myoepithelial cells
Mixed
Benign Benign cells resembling epithelial components (luminal and/or myoepithelial) and mesenchymal cells that have produced cartilage,
bone or fat in combination with fibrous tissue
Organization international classification system, published in
1999, which combined histology, morphology and prognostic
information (Table 1) (83); further refinement was brought about
through advances in understanding CMT biology. These results
subsequently led to the recognition and incorporation of new
histologic subtypes into the classification system (84).
Grading systems, such as the Elston and Ellis method
are also commonly used to provide prognostic information
by providing a malignancy score (85). CMT can also occur
in multiple glands at the same time with 60% of tumors
located with the caudal glands. CMT can also have substantial
histological variation both within a single specific tumor and
between different tumors in the same dog (86, 87). CMT can
be purely of epithelial (simple adenoma or simple carcinoma)
or mesenchymal (fibroadenoma, fibrosarcoma, osteosarcoma, or
other sarcomas) origin; however, some consist of a combination
of epithelial and myoepithelial tissues (complex adenoma or
complex carcinoma) or epithelial and mesenchymal tissues
(benign mixed tumors or carcinosarcoma) (84). Approximately
50% of all CMT are malignant (71, 88), the majority of which
are carcinomas.
Inflammatory mammary carcinoma is a rare and specific form
of CMT (89, 90). The disease has a similar incidence rate to
the equivalent disease in HBC, accounting for ∼7% and 5%
of all canine and human mammary tumors, respectively (89,
91). Inflammatory mammary carcinoma is locally invasive with
genetic, biological and clinical characteristics that differ from the
other forms of mammary cancers (89, 92) and is histologically
diagnosed by invasion of dermal lymphatic vessels by neoplastic
emboli (93).
Canine Mammary Tumors and Metastatic
Disease
Depending on the subtype diagnosis, CMT can be fatal due to
the development of metastatic disease. Studies have shown that
50% of canine mammary carcinomas metastasise to local lymph
nodes. Lymph node involvement invariably leads to distant
metastases, which is seen most commonly in the lung, although
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TABLE 2 | Canine mammary tumor prognostic factors (DFS, disease-free survival; OS, overall survival) [adapted from Sleeckx et al. (97)].
Factor Effect on prognosis
Age Increased age at diagnosis can reduce DFS and OS (98–101)
Tumor size Increased tumor size can reduce DFS and OS (99–103). Dogs with a tumor size of 3–5 cm can have a median OS of 22 months;
whereas dogs with tumors >5 cm can have a median OS of 14 months
Skin ulceration Presence of skin ulceration can reduce DFS and OS (98, 99, 101)
Histological subtype Subtype classification can correlate with prognosis (83, 99, 101, 103, 104): Anaplastic carcinomas can have a median OS of 2.5
months; solid carcinomas can have a median OS of 16 months, whereas tubulopapillary carcinomas can have a median OS of 21
months
Tumor stage Tumor stage at diagnosis correlates with OS (103, 104). Stage I: median OS of 24 months; Stage II: median OS of 12 months; Stage
III: median OS of 15 months; Stage IV and V: median OS of 6 months
Grade Tumor grade at diagnosis correlates with 2-year survival (99, 101, 105). Grade I: 100%; grade II: 53.3%; grade III: 13.5%
Lymph node metastasis The presence of lymph node metastasis at diagnosis correlates with 2-year survival (98, 99, 101, 103–107). 85% of dogs without
lymph node metastasis will be alive 2 years post-surgery, compared with only 21% that have lymph node metastasis
Distant metastasis The presence of distant metastasis at diagnosis correlates with OS (103, 106). Dogs without metastases at time of surgery can have
median OS of 28 months compared with only 5 months for dogs with metastasis
Expression of ER and PR Low expression correlates with reduced DFS and OS (102, 106, 107)
Expression of Cox-2 High expression correlates with reduced DFS and OS (108–111)
Expression of proliferation
markers
High expression correlates with increased risk of metastasis and reduced DFS and OS (98, 101, 106, 107)
metastatic bone lesions can also occur (94, 95). This clinical
course is similar to HBC, where ∼7% of women will present
with metastatic disease and 20% of those with local disease will
eventually develop metastatic lesions (96). Although research has
identified several prognostic markers such as age, tumor size,
local/distant metastases, clinical stage and histological subtype
that can separate human and canine patients into cohorts that
have greater recurrence or mortality risk (Table 2) (98, 102,
105–107, 112–114), a detailed understanding of the molecular
mechanisms which influence how these cancers metastasise
remains unclear.
To investigate the value of CMT as a metastatic model,
studies have investigated both gene (115) and protein (116)
signatures identified in metastatic CMT and compared them
with equivalent human samples. Metastatic CMT were shown
to have ∼1,000 genes that were significantly differentially
expressed compared to non-metastatic carcinomas. Up-regulated
genes were associated with cell cycle regulation, DNA damage
repair, matrix modulation, protein folding and proteasomal
degradation. These results are similar to a meta-analysis study
usingmetastatic HBC expression profiles which found significant
up-regulation of cell cycle andDNA replication pathways. Down-
regulated genes were associated with cell differentiation, growth
factor pathways, focal adhesion pathways and regulators of actin
organization. Of the differentially expressed canine genes, 25%
were found to be associated with HBC; expression profiles of
metastatic CMT also contained parts of a human prognostic gene
signature (115).
Similar results to those observed at gene level have been
identified at the protein level (116). One study identified
21 proteins with significant changes in expression between
metastasising and non-metastasising CMT; these proteins
were predominantly associated with cellular functions related
to metastasis including extracellular matrix remodeling, cell
adhesion and resistance to hypoxia. Higher expression levels
of proteins involved with proliferation (such as proliferating
cell nuclear antigen) and cell motility (tropomyosin 3, Coronin
1A, adenosine deaminase) were also identified in metastasising
compared with non-metastasising carcinomas. The same study
also showed thatmetastatic cells had increased protein expression
of free radical scavengers, which may protect the cells from
hypoxic and oxidative stress caused by rapid tumor growth
and poor vascularisation. While the expression of thioredoxins
had not been previously investigated in CMT, increased
expression levels have been found in poorly differentiated
human colorectal and hepatocellular carcinomas. Literature
searches using the 21 differentially expressed proteins in the
metastatic CMT showed that 19 of them had previously been
associated with either malignancy or metastasis in a variety
of human cancers. Furthermore, 9 of the proteins had a
similar malignancy-associated protein expression pattern as seen
in HBC.
The partially overlapping transcriptome and proteome of
metastatic CMT and HBC suggests that there are underlying
comparable mechanisms involved in mammary carcinogenesis
and pathogenesis between the 2 species and provides
evidence that metastatic canine carcinomas are a suitable
translational model for human breast tumors which could
be used to determine prognostic and predictive molecular
signatures and identify therapeutic targets. Furthermore, the
differential gene and protein expression profiles in metastatic
and non-metastatic carcinomas could predict prognosis
and identify molecular pathways and networks involved in
CMT metastasis.
Molecular Markers
The use of molecular markers, such as hormone or signaling
receptors in HBC diagnosis has had a major influence on patient
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treatment regimens. Markers have the potential to predict which
patients will most likely respond to certain treatments and
provide prognostic information. Although these markers are
not routinely used in veterinary medicine, increasing evidence
suggests that these human-derived molecular markers might be
similarly useful for CMT evaluation.
Hormones
Steroid hormones (estrogen and progesterone) and their
receptors play significant roles in HBC development.
As in women, CMT are predominantly hormone-
dependent; this is evidenced by the fact that, as with early
pregnancy/oophorectomy in women, early spaying in dogs
is linked with lower disease incidence. ER and PR have also
been identified in ∼70% of benign and 60% of malignant CMT
(117–119); this is similar to that seen in HBC, where∼60–70% of
all tumors contain these receptors (120–122). In humans, ER and
PR are useful prognostic indicators; ER expression for example
is known to be associated with increased DFS and OS of breast
cancer patients (119). ER expression is also a predictor of tumor
hormone dependency and thus response to endocrine therapy
(123–125). Several studies have now shown that, like in humans,
ER and PR expression can also be prognostic and predictive in
CMT, with a decrease in hormonal dependency commonly seen
in malignant tumors (122, 126). Normal mammary gland tissue,
mammary dysplasia, and benign tumors have been shown to have
higher ER expression levels than malignant tumors (118, 127),
with a recent study demonstrating that dogs with ER−/PR+
tumors had significantly worse survival rates in comparison to
dogs with ER+/PR+ tumors. Dogs with ER−/PR− tumors had
the most guarded prognosis of all (122). Higher ER expression
levels have also been shown to occur in the tumors of young dogs,
those that remain genitally intact and in dogs that have regular
oestrous cycles (107). Metastatic lesions are also frequently
ER−/PR− and malignant PR− tumors have been shown to
proliferate at higher rates than PR+ tumors. A further study has
also shown that ER expression is lower in malignant compared
with benign tumors, with lower expression also identified in
larger tumors and in those where skin ulceration was present
(107). Lymph node involvement and the development of distant
metastasis was also associated with low ER expression levels.
Proliferation, assessed by proliferating cell nuclear antigen, was
found to be negatively correlated with ER expression levels,
supporting results seen in HBC that well-differentiated tumors
can maintain a hormonal regulation of cell division leading
to lower proliferation rates. This study also showed that ER
expression, Ki-67 index, and age were predictors of DFS, and that
age, lymph node status and ER expression were all prognostic
for OS. These results have been supported by a large study of
350 dogs diagnosed with malignant carcinomas in which tumor
size larger than 20mm, positive lymph node, a histological
grade III, ER− status and high Ki-67 proliferation index were all
prognostic factors for poor OS. Overall, these studies indicate
that molecular markers, especially ER, in CMT can be used as
prognostic indicators and predictors of DFS and OS and could
be useful in selecting appropriate hormonal therapy as is the case
in HBC (106).
Signaling Receptors and Associated Pathways
As described earlier, HER2 is an intensively studied proto-
oncogene in HBC which functions to promote tumor growth,
cellular differentiation and survival. Approximately 30% of all
HBC cases express HER2, this subtype has high metastatic
potential and carries a poor prognosis (41–43). HER2 protein
overexpression is both prognostic for disease outcome and
predictive for the response to targeted therapies (128) and in
the vast majority of cases results from HER2 gene amplification
(129). Fluorescence in situ hybridization (FISH) is a sensitive
technique for evaluating HER2 gene status in terms of gene
amplification and copy number which may be superior to IHC
HER2 assessment. One study showed that patients classified as
HER2 positive by FISH but negative by IHC had poorer survival
rates than those who had HER2 overexpression in the absence
of gene amplification (130). Chromogenic in situ hybridization
(CISH) is an alternative technique to FISH which has been
shown to be an accurate, practical, and economical approach to
determining HER2 status in HBC (129). In veterinary medicine,
investigations into CMT HER2 expression have not been as
abundant as compared with that in human medicine. Several
studies have identified either HER2 protein or gene expression
in ∼35% of malignant CMT (131–134); however these studies
did not investigate the simultaneous analysis of HER2 protein
and gene status. One study has investigated the relationship
between HER2 gene and protein expression in CMT through the
use of CISH and IHC. HER2 protein overexpression was found
in 17.6% of the carcinomas tested; however, these cases were
not associated with gene amplification. The authors suggested
that CMT could be translational models of HBC where HER2
overexpression occurs in the absence of gene amplification
(135). HER2 expression has been correlated with mitotic index,
histological grade and tumor size (131, 133, 136). AlthoughHER2
expression is thought to be associated with poor prognosis (137)
some studies have shown no difference in HER2 expression
between benign and malignant tumors (132, 138, 139). It has
therefore been suggested that HER2 expression may be involved
in carcinogenesis but may not play a significant role in malignant
transformation; as yet, its role as a marker of malignancy in CMT
undetermined. Through genetic sequencing it has been shown
that there is a high degree of homology between the human
and canine HER2 antigens; this has led to the suggestion that
human antibody-based immunotherapies such as trastuzumab or
pertuzumab could be utilized in HER2 expressing CMT (140).
EGFR has been highlighted as a potential prognostic
molecular marker and possible therapeutic target in triple
negative HBC (ER−/PR−/HER2−) (141). In CMT high EGFR
expression has been associated with increased angiogenesis,
large tumor size, tumor necrosis, higher mitotic rates, advanced
clinical stage and malignancy (142–144). However, its role in
mammary carcinogenesis or prognosis is unclear. Although
studies have shown a tendency toward shorter DFS and
OS for dogs with CMT expressing EGFR, these associations
have failed to reach statistically significant levels (143).
Downstream pathways of EGFR have also been implicated
in HBC pathogenesis; results from the first genome-wide
comparative analysis of canine and human mammary tumors
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showed up-regulation of numerous pathways related to increased
proliferation, whereas pathways involved with cell development,
communication and matrix adhesion were down-regulated. This
study also demonstrated significant homology between canine
and human cancers in terms of changes to known cancer-
related signaling pathways including KRAS, PI3K/AKT, MAPK,
PTEN and Wnt-β-catenin (145). The PI3K/AKT pathway is a
very well-studied pathway that is involved in regulating cellular
transformation, proliferation and survival. In HBC, genetic
aberrations can lead to PI3K/AKT pathway activation through
the presence of activating point mutations at phosphoinositide-
3-kinase, catalytic, alpha polypeptide (PIK3CA), mutation of v-
akt-murine thymoma viral oncogene homolog 1 (AKT1) and
loss of phosphatase and tensin homolog (PTEN) activity (146–
151). Active PI3K/AKT signaling has been identified in CMT in
association with a decrease in expression of the tumor suppressor
gene PTEN. Loss of PTEN has been suggested as a prognostic
marker in CMT (145, 152, 153).
E-cadherin is an important membrane bound cell adhesion
molecule and tumor suppressor gene which is commonly
expressed in epithelial tissues. Loss of E-cadherin can occur in
HBC and CMT and is associated with tumor size, histological
grade, stage of disease and prognosis (154–156). Loss of
E-cadherin is also a key feature of epithelial-mesenchymal
transition (EMT), which can promote metastasis through
increasing a cell’s ability to migrate and invade (157). Another
member of the cadherin family that appears to be involved
in HBC pathogenesis is P-cadherin. P-cadherin is expressed
by mammary tissue myoepithelial cells and has been found
to be overexpressed in high-grade invasive breast carcinomas.
Expression is associated with poor prognosis as the molecule
is known to enhance cell invasion and tumor aggressiveness
(158). Similar results have been found in CMT, with higher
P-cadherin expression levels being associated with malignant
histologic subtypes and increased invasive properties (154).
The p53 tumor suppressor gene plays a major role in the
prevention of cellular malignant transformation, acting through
its control of the cell cycle, cell growth, DNA repair mechanisms,
apoptosis and autophagy (159). Through these mechanisms, p53
can influence a cells fate following DNA damage and can confer
resistance to tumourigenesis in human mammary epithelial cells.
Conversely, p53 gene mutations can lead to deregulated cell
proliferation and tumourigenesis. These aberrations are more
commonly found in triple negative HBC and high expression in
this subtype correlates with poor prognosis (160). The frequency
of p53 mutations in CMT is ∼20%, which is similar to that
seen in HBC (161–163). In HBC, accumulation of p53 nuclear
protein, resulting from p53 gene mutation, has been shown
to be correlated with poor OS (162, 164). In CMT, p53 gene
mutations and protein overexpression are considered predictors
of malignancy and poor prognosis (163, 165, 166).
Although only a limited number of molecular markers have
been highlighted here, there are a significant number of others
which have been investigated for their similarities between HBC
and CMT. These include insulin-like growth factor, growth
hormone, Wnt signaling, mucins, heat shock proteins, CEA, CA
15–3, VEGF and cyclooxygenases (137, 167). The similarities
observed between mammary tumors occurring in dogs and
humans in terms of target genes and molecular signaling
pathways provides significant evidence that this canine cancer
model can be regarded as a homolog for human cancer biology.
Research into CMT could facilitate cross-species development of
pathway-targeted therapeutic agents, identification of prognostic
or predictive biomarkers and evaluation of drug responses.
Canine Mammary Cancer Subtypes
Subtype classification of CMT has been investigated in a number
of studies which typically use immunohistochemical expression
of various cellular markers. One large study used PR, ERα,
HER2, EGFR, Ki-67, and CK5/6 and as the molecular markers.
Evaluation of their expression levels identified several distinct
subtypes including luminal A (14.3%), luminal B (9.4%), triple-
negative basal-like (58.6%), and triple-negative non-basal-like
(17.7%), although no HER2-overexpressing CMT were observed
(168). A further study based CMT classification on HER2 and
ER expression which identified luminal A (ER+/HER2−, 44.8%),
luminal B (ER+/HER2+, 13.5%), basal-like (ER−/HER2−,
29.2%) and HER2-overexpressing (ER−/HER2+, 8.3%) subtypes
(169). The PAM50 human classification system has also been
used to subtype CMT. This analysis was repeated 100 times,
ensuring that each TCGA tumor was sampled at least once.
Notably, in 82 of 100 times, all canine simple carcinomas and ER
complex carcinoma (ID 518) groups clustered with the human
basal-like tumors. The remaining canine complex carcinomas (all
ERβ), however, failed to cluster with any specific human subtypes.
This study explained these results were due to the canine
tumors not possessing HER2 overexpression or amplification.
Furthermore, consistent with the basal-like subtype a portion of
these canine mammary carcinomas also harbored copy number
abnormalities and were ER−, with DNA repair and cell cycle
related genes significantly up-regulated. Basal-like HBC are
inherently aggressive which carry a poor prognosis. Currently
there are no effective therapies which can be used against this
subtype. However, studies such as the ones described here have
provided evidence for the use of canine mammary carcinomas
as a model to study basal-like HBC. This model therefore
could provide translational information toward understanding
and treating this breast cancer subtype (170). Although there
appears to be some variation in the specific subtypes and their
incidence levels identified in each study, overall the results
suggest that subtype classification is associated with prognosis;
luminal A subtypes exhibit significantly longer DFS and OS
compared to triple-negative carcinomas. The results from these
CMT studies demonstrate the molecular heterogeneity of the
disease and highlight the models use for studying breast cancer
carcinogenesis and pathogenesis.
BRCA1, BRCA2 Mutations
Several genes, including CHEK2, HER2, RCAS1, TP53, FGFR2,
LSP1, MAP3K1, and TOX3 are known to increase the risk
of HBC (171–174). The development of breast cancer is
thought to be polygenic, where tumourigenesis is influenced
by numerous loci, each contributing a small risk to disease
development (175, 176). However, the most commonly studied
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genes are BRCA1 and BRCA2 (BRCA1/2). The BRCA1/2 genes
are members of the granin family. They function as tumor
suppressors playing critical roles in maintaining genome stability
largely through regulating transcription and controlling the
DNA damage response, DNA repair and cell cycle (177).
Mammary tumor development in dogs and women has been
associated with deregulation of BRCA1/2 gene function (145,
178, 179). BRCA1/2 germline mutations account for ∼5–10%
of all HBC cases (180, 181), with inherited BRCA1/2 mutations
increasing the risk of breast cancer up to 84% (182–184). Most
BRCA1/2 gene mutations occur through non-sense mutations,
indels, rearrangements, or splice variants which cause the
proteins to become truncated (185, 186). BRCA2 is commonly
overexpressed and associated with poor prognosis in HBC,
whereas decreased BRCA1 expression is frequently observed
during disease progression (187–189). The histology of breast
cancers in women predisposed by BRCA1 and BRCA2mutations
differs in several ways. BRCA2 and BRCA1 mutations have also
been associated with male breast cancer and ovarian cancer,
respectively. When BRCA1 breast tumors are compared with that
of sporadic cases they are more likely to show higher grades of
malignancy, be classified as ER− and PR− and carry a worse
prognosis (190).
As dogs have a long history of inbreeding with low levels of
genetic variation, it has been suggested that CMT development
in a single breed should have a more defined homogenous origin
compared with that of HBC, which occurs within a diverse
and much larger population. In theory this concept should
allow for the identification of breed specific CMT risk factors.
One study investigated the development of CMT in English
springer spaniels and identified that the BRCA1/2 genes were
associated with a 4-fold increase in the risk of developing CMT
(191). However, this study did not look at gene mutations
and further investigations are required to understand them and
identify functional mechanisms, i.e., how these genes influence
tumourigenesis. A more recent CMT study has shown that
BRCA2 messenger RNA expression decreases in adenomas but
increases in mammary carcinoma lymph node metastases when
compared with non-neoplastic mammary epithelium (192). A
reduction in the nuclear expression of BRCA1 has been shown to
occur in CMTwhich was associated with high proliferation index
and loss of ER. These findings were more significantly associated
with malignant phenotypes (193). These studies provide further
evidence that CMT is an excellent model for HBC with a specific
focus on a genetic hereditary component of the disease.
Mammography and Ultrasound Imaging
Screening procedures and diagnosis of HBC commonly involves
the use of ultrasonography and x-ray mammography (194). X-
ray mammograms can be useful to diagnose DCIS through
the identification of microcalcifications which can be present
in up to 72% of cases (194, 195). Ultrasound and X-ray
mammography have been investigated in canine pre-invasive
and invasive mammary tumors to assess whether the disease
has similarities to HBC in terms of imaging appearance
(196). Canine mammary mammographic and ultrasonographic
abnormalities in pre-invasive lesions, benign and malignant
tumors were found to be similar to those commonly seen
in HBC, including the presence and distribution pattern of
microcalcifications and macrocalcifications. The identification
of calcification was also associated with malignancy. This
study indicated that CMT form similar microcalcifications and
macrocalcifications to HBC and suggested that a comparable
carcinogenesis processmay be occurring between the two species.
Furthermore, the authors concluded that sonographic and
mammographic characteristics of benign and malignant CMT
could be associated with histopathological diagnosis and that
mammographic categorization was therefore a precise method
for the detection of malignant CMT.
Treatment and Prognosis
As in human cancer patients, disease staging for CMT is
mandatory before beginning definitive treatment. Staging would
typically include blood work and thoracic and/or abdominal
radiographs and cytologic evaluation (87, 97). Surgery with either
lumpectomy or radical mastectomy remains the most widely
accepted treatment option for CMT (197). One large prospective
study found no significant difference in local recurrence rates or
OS between dogs receiving either a simple lumpectomy or radical
mastectomy (86); however, a further smaller study identified
that 58% of dogs which received local removal of individual
mammary tumors developed new tumors in the remaining
ipsilateral mammary glands, suggesting more radical surgery
may be required (198). Concurrent ovariohysterectomy may also
improve survival rates for ER+ tumors and those dogs with
raised serum estrogen levels (199). In one recent study involving
350 dogs diagnosed with invasive mammary carcinomas, OS
after mastectomy was only 11 months (106). Chemotherapy
is commonly used to treat triple negative or metastatic HBC
and, although only limited studies have been conducted for
its use in the treatment of CMT, various chemotherapeutic
agents are commonly used in dogs to treat a variety of other
cancers (97). A small case study has shown that post-operative
5-fuorouracil and cyclophosphamide did improve DFS and
OS in dogs with malignant mammary tumors compared with
dogs that received only surgery (200). Inflammatory mammary
carcinomas have an extremely poor survival rate, with no
effective treatment. Multimodal therapy, including neoadjuvant
chemotherapy and/or RT before mastectomy has improved
DFS and OS times in women with the condition. One study
has investigated the use of chemotherapy (mitoxantrone or
mitoxantrone combined with cyclophosphamide and vincristine)
in addition to palliative treatment of dogs with inflammatory
carcinomas. Although the study did show that chemotherapy
improved survival times from 35 to 57 days, the prognosis
remained extremely poor (93). Hormonal therapy is a commonly
used treatment option in humans with ER+ breast cancer. In
dogs however the use of anti-oestrogens, such as tamoxifen,
for the treatment of CMT has only been reported in a limited
number of clinical studies. The results of these canine studies
have also provided conflicting results (201, 202). Anti-estrogen
therapy can also cause significant side effects in dogs which
includes vulvar swelling, vaginal discharge, pyometra (intact
females) and stump pyometra (spayed females) (202, 203). RT is
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seldom used in the treatment of CMT but could be considered
to aid local disease control for incompletely resected tumors
or as a palliative treatment for non-resectable or inflammatory
mammary carcinomas. Further investigations to determine the
role of RT in the treatment of CMT are required because of the
significant role it plays in the treatment of HBC (197). These
studies provide evidence that the potentially aggressive nature
of CMT, especially in the case of invasive and inflammatory
carcinomas, can allow clinical trials to be completed in shorter
time frames than human trials would allow. Rapid generation
of data could then be used to aid the design of human trials,
potentially improving the selection of drugs taken forward (106).
Limitations and Achievements Associated
With the use of Naturally-Occurring Canine
Cancer Models for Translational Research
Although comparative oncology is not a new concept, the idea
of integrating canine studies of naturally-occurring cancers into
the drug development process is still not commonly practiced.
Lack of model awareness and poorly coordinated infrastructures
between veterinary hospitals, oncologists, researchers and
pharmaceutical companies are important factors which have held
back the potential of using such a model (63). Understanding
the risks and challenges that are preventing the use of these
naturally-occurring canine cancer models is essential if we are to
overcome some of the limitations associated with traditional drug
development strategies.
Researchers might consider that the increased time and
monetary investments required to complete canine studies,
compared with resources typically needed in murine models,
are major limiting factors for their use. Study costs and detailed
budgets are mandatory requirements for canine studies and will
need to include factors such as drug production (the larger size
of dogs compared to mice will mean larger drug quantities are
required), recruitment of the required number of dogs, obtaining
clinical resources and data analysis. Ultimately, the cost of a
canine study will depend on the specific scientific question that
needs to be answered and its defined clinical endpoint; these
important factors must be established first as they will dictate the
design of the trial. The addition of diagnostic procedures, tumor
biopsies, imaging, follow-up assessments, sample collection and
processing all incrementally add to study costs (65). However, it
must be stressed that these types of procedures add significant
value to the drug development process and can produce data
which is difficult or impossible to obtain using murine models. If
an integrated canine model approach is successful at prioritizing
drugs for development and use in humans, then these study costs
will be minor and offset by the substantial cost reductions seen in
subsequent human clinical trials.
Other important factors that researchers need to consider if
dogs are to be used pre-clinically is that the studies must be
conducted using standard guidelines with ethical approval and
informed owner consent. The lack of readily available protocols
might deter researchers from using the model. Results from such
studies should be reported in a timely manner. In the USA,
an electronic reporting system, developed by the Comparative
Oncology Trials Consortium (COTC), allows data to be acquired
in real-time and provides a means by which study results can be
monitored (65); unfortunately, systems such as this are not yet
widely available.
A significant advantage of using CMT for HBC research is
that the disease is the most commonly diagnosed cancer in
female dogs, with an incidence rate greater than that seen in
the human population (1, 66, 71). Although there is potentially
a large cohort of dogs that could be recruited into studies,
a significant limitation of using this canine population for
HBC research is that the current standard of care treatment
options between the 2 species differ significantly. As described
earlier in the review, regardless of tumor subtype (excluding
inflammatory mammary carcinomas) surgical resection alone
is the most commonly used treatment option for CMT. This
contrasts with HBC, where subtype can influence treatment and
typically consists of patients receiving multimodal therapy. These
differences in treatment regimes can make the generation of a
translational clinical trial difficult. Recruitment of CMT patients
into a clinical trial may also have challenges. Although there
may be a large population of dogs suitable for recruitment,
informed owner consent is required before enrolment into the
trial, which can be difficult to obtain. Currently, there is a
lack of patient stratification for those dogs receiving surgery
alone; therefore, justification for inclusion into trails investigating
adjuvant therapies may be difficult. Ultimately these CMT studies
may therefore be restricted to dogs receiving palliative treatment,
those that failed standard treatments or those which are unfit
for surgery. However, recruiting these dogs may be difficult as
owners will typically opt for euthanasia due to poor prognosis.
Increasing owner awareness by providing evidence of why canine
studies can help both veterinary andmedical communities would
help overcome these issues and improve patient recruitment.
One of the accepted advantages of using murine cancer
models, including breast, is that the tumors they produce are
genetically homogenous and as such, tumors in different mice
will respond in similar ways to a specific drug (204). Subtle
effects can be more easily identified, and animal sample sizes can
therefore be reduced. Although in this review we have shown that
CMT are similar to HBC, the tumors that occur in both species,
even those classified as the same subtype, can have considerable
heterogeneity. Even though clinical trials can be specifically
tailored to a specific tumor subtype, this inherent mammary
tumor heterogeneity will ultimately result in a variation of tumor
responses to drugs. This may require increased numbers of dogs
to be recruited and larger sample sizes to be obtained. However,
it is these types of trials, that incorporate tumor heterogeneity,
that will ultimately provide a more translational and clinically-
relevant model that will improve drug development strategies.
An excellent example of the use of naturally-occurring canine
cancers in a phase I clinical trial involved the investigation
of the safety and efficacy of a novel receptor tyrosine kinase
(RTK) inhibitor, SU11654 (205). This synthetic compound was
developed to inhibit multiplemembers of the split-kinase domain
family of RTKs, including platelet derived growth factor receptor
(PDGFR), vascular endothelial growth factor receptor (VEGFR),
FLT3, and KIT. Phase I trials were undertaken as SU11654
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had shown anti-proliferative and anti-angiogenic activity in in
vitro studies and in in vivo murine xenograft experiments (206).
Fifty-seven dogs over a 1-year period that were diagnosed with
a variety of naturally-occurring tumors, including mammary
carcinomas, which had failed conventional therapy or for which
no therapeutic alternative was available were recruited into the
study. As these dogs had a very poor prognosis other selection
criteria such as estimated life expectancy of >6 weeks and
adequate organ function were included into the recruitment
process to allow the study to run over a long enough time
period to allow toxicity and tumor response data to be obtained.
Results showed that the greatest tumor response rates were seen
in mast cell tumors (MCT) and that dogs with MCT possessing
KIT mutations were much more likely to respond to therapy
than those tumors with wild-type KIT. Aberrant KIT signaling
in MCT can be due to activating mutations, similar to those
found in gastro-intestinal stromal tumors in humans, consisting
of internal tandem duplications in the juxtamembrane domain
of KIT which results in constitutive receptor phosphorylation.
In terms of the 5 mammary carcinoma cases included in the
study, serial thoracic CT scans identified regression of pulmonary
metastases in 2 cases (partial responders: 21 weeks and >60
weeks) and no change in size of pulmonary metastases in a
further 2 cases (stable disease: 27 and 38 weeks). Although this
study did not investigate the mode of action of SU11654 in these
CMT cases, aberrant VEGFR, PDGFR, and KIT expression has
been identified in HBC (207–209) with high KIT expression
levels having also been identified in CMT (210). The authors
suggested that given the similarities between canine and human
cancers in terms of tumor biology and the presence of analogous
RTK dysregulation, SU11654 or similar compounds could elicit
comparable biological responses in both species. Further studies
confirmed the benefits of using SU11654 in canine MCT (211)
and toceranib (PalladiaTM) became the first dog-specific anti-
cancer drug to gain clinical approval.
Following the success of these trials a sister compound
to toceranib called sunitinib (SutentTM), was later clinically
approved for the treatment of renal cell carcinoma and
gastrointestinal stromal tumors in human patients; however,
its role in the treatment of HBC patients remains open to
debate. One recent systematic review evaluated the efficacy of
using sunitinib alone or in combination with chemotherapy for
the treatment of advanced HBC and suggested that sunitinib
produced no clinical benefit. However, the authors suggested
that further studies that stratify patients based on perhaps
molecular markers are warranted to fully ascertain sunitinib’s use
in HBC (212).
Although this canine phase I clinical trial is just one example,
it provides evidence of how the early integration of naturally-
occurring canine cancers into the drug development process
can be implemented successfully and demonstrates how the
previously described limitations can be overcome.
CONCLUSIONS
Naturally-occurring CMT have significant potential for use
as a model to study various aspects of HBC biology. The
disease in both species shares similar etiology, histopathological
classification and pathogenesis, with known oncogenic drivers
such as HER2 and estrogen signaling. The shorter lifespan of
dogs and aggressive nature of the disease means that clinical trials
involving new therapeutic agents can be completed far quicker
and cheaper than human phase O-IV studies. The results from
the integration of CMT patients into clinical trials as pre-clinical
models could feed back on the design of subsequent human trails.
The aim of using translational models in this way would be to
reduce the high rates of failure currently seen in human proof-
of-concept studies. This concept would ultimately save time and
money. The successful adoption of the translational aspects of
the CMT model into cancer research would not only improve
our molecular understanding of breast cancer, but also improve
pre-clinical research and ultimately the treatment of canine and
human breast cancer patients.
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